Open Access Critical Evidence Review

Distinct signaling properties of IRS-1 and IRS-2 in mediating insulin/IGF-1 action - A review of the evidence

The study shows that IRS-1 and IRS-2, while similar, direct different signals following stimulation with IGF-1 in murine brown adipose cells. This makes it plausible that their balance influences the insulin response in tissues. Independent confirmations are primarily animal-based and mechanistic; complete, large-scale direct demonstrations in humans are currently lacking.

Cite this article
Mondini, M. (2026). Distinct signaling properties of IRS-1 and IRS-2 in mediating insulin/IGF-1 action - A review of the evidence. Life Science Hub Journal. DOI: 10.5281/zenodo.24307072. https://lifesciencehub.info/en/distinct-signaling-properties-of-irs-1-and-irs-2-in-mediating-insulin-igf-1-action-a-review-of-the
LIFE Science Hub - Journal of Science · 2026 / Nov

DOI 10.5281/zenodo.24307072

Article history
Dates
  • Published 16/11/2026
  • Updated 17/11/2026
Revisions
  1. v1.0 — 16/11/2026 Initial publication of the article.
  2. v1.1 — 17/11/2026 Editorial update of content, sources or references.

LIFE Science Hub keeps a record of every published version of the article to ensure editorial transparency. Future revisions will appear here.

Two similar but distinct protein signaling pathways, illustrated as molecular networks linked to IRS-1 and IRS-2 following IGF-1 stimulation.
Conceptual representation of insulin signaling: two related but different protein platforms, IRS-1 and IRS-2, drive distinct intracellular pathways. The image highlights the molecular balance underlying the metabolic response.

ABSTRACT

The analyzed study examined whether IRS-1 and IRS-2, two proteins that transmit signals from insulin and insulin-like growth factor 1 (IGF-1), produce different intracellular responses. In brown adipose tissue precursor cells obtained from mice, the authors compared normal cells with cells lacking IRS-1 or IRS-2, measuring thousands of chemical protein modifications after stimulation with IGF-1. Approximately 10% of the 6,262 phosphorylation sites detected were found to be regulated by IGF-1, with preferential profiles associated with the presence of each isoform.

In section 4.2 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the publication contributes to the narrative that IRS-1 and IRS-2 are not fully interchangeable and that their proper balance supports the efficiency of insulin signaling. Independent studies in mice confirm a particularly relevant role for IRS-1 in skeletal muscle and for IRS-2 in the liver and central nervous system. However, the functions of the two proteins partially overlap, and direct evidence in humans remains limited.

Analyzed study

Distinct signalling properties of insulin receptor substrate (IRS)-1 and IRS-2 in mediating insulin/IGF-1 action

Rabiee A, Krüger M, Ardenkjær-Larsen J, Kahn CR, Emanuelli B

Cellular signalling, 2018

DOI: 10.1016/j.cellsig.2018.03.003

PMID: 29550500

PMCID: PMC5951756

The research question was whether IRS-1 and IRS-2, adapter proteins that link the insulin and IGF-1 receptors to other intracellular signals, transmit identical or partially different biological instructions. The hypothesis was that the strong structural similarity between the two isoforms did not imply complete functional equivalence.

The relevance to paragraph 4.2 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi lies precisely in this point: the efficiency of the insulin signal depends not only on the generic presence of IRS proteins, but also on the specific isoform available and its ability to activate certain intracellular pathways.

The study can demonstrate that, in a murine cell model stimulated with IGF-1, the loss of IRS-1 or IRS-2 is associated with different phosphorylation profiles. However, it cannot directly demonstrate that IRS-1 is predominant in human muscle, that IRS-2 is predominant in the human liver or central nervous system, nor establish clinical consequences such as individual diabetes risk.

Materials and methods of the original study

The study used murine brown preadipocyte cell lines, which are precursor cells of brown adipose tissue, obtained from normal mice and from mice genetically lacking IRS-1 or IRS-2. The cells were evaluated under basal conditions and after stimulation with IGF-1, a molecule that partially uses the same intracellular mediators as insulin.

The authors applied SILAC, a technique that labels proteins with amino acids distinguishable by mass spectrometry, to precisely quantify phosphorylation changes. Phosphorylation is the addition of a phosphate group to a protein; it can modify the protein's activity and therefore the direction of the cellular signal.

A phosphoproteomic profiling based on mass spectrometry was performed, which is an extensive analysis of the phosphorylated proteins present in the cells. The authors also used computational predictions to identify the kinases potentially responsible for the observed modifications. The number of biological cultures, exclusion criteria, IGF-1 concentrations, detailed exposure times, and complete statistical methods are not reported in the available material, which consists only of the abstract.

Results

The overall result is that IGF-1 did not trigger an indiscriminate response. It selectively modified many proteins involved in signal transduction, and some modifications were more dependent on IRS-1 while others were more dependent on IRS-2.

The authors identified 6,262 unique phosphorylation sites. Of these, approximately 10% were found to be regulated by IGF-1 stimulation. Both previously known targets of insulin/IGF-1 signaling and targets not previously described in the context of the study were observed, including Nuclear Factor I X and Semaphorin-4B.

Computational analyses indicated protein kinase B, also known as AKT, protein kinase C, and cyclin-dependent kinases as likely mediators of a portion of the phosphorylation events. Notably, the presence of IRS-1 was preferentially associated with signals involving PDHK1, MAPK3, and PKD1; the presence of IRS-2 was preferentially associated with signals involving PIN1 and protein kinase C beta.

In simple terms, the two IRS proteins functioned as similar but not identical platforms: following the same stimulus, they favored partially different sets of intracellular messages. The abstract does not report P-values, confidence intervals, percentage variations for each individual site, nor independent functional validations for all identified targets.

Interpretation

The biological significance is that the cell does not necessarily use IRS-1 and IRS-2 as two equivalent copies of the same component. The relative availability of the two isoforms can alter which signals are prioritized following the activation of the insulin or IGF-1 receptor.

This supports the narrative segment of "The Choice to Live in Health or Illness" by Dr. A. Colonnese and R. Panzironi, which states that the correct balance, tissue-specific expression, and functional integrity of IRS isoforms contribute to the efficiency of insulin signaling. The publication subject to the Review of evidence directly documents, above all, the non-equivalence of the downstream signals of the two proteins, not their distribution in various organs.

The observed difference concerns murine brown adipose cells and stimulation with IGF-1. It is therefore mechanistic evidence, useful for understanding how different functions can emerge, but not a clinical demonstration in humans. Furthermore, the predictions regarding kinases are computer-generated indications and require targeted experimental confirmation.

Independent supporting evidence

Initial independent confirmation concerns skeletal muscle. In mice lacking IRS-1, insulin stimulation resulted in reduced PI3-kinase activation, glucose transport, and protein synthesis in the muscle. In the liver of the same animals, however, the activation of PI3-kinase and the MAPK pathway was not significantly reduced. The authors also observed that IRS-2 phosphorylation in the liver was approximately equal to that of IRS-1 in normal mice, whereas in the muscle, the IRS-2 signal was only 20-30% of that of IRS-1. This animal study directly supports the claim that IRS-1 plays a primary role in muscle insulin signaling and shows that compensation by IRS-2 is tissue-dependent [1].

A second study in mice evaluated the absence of IRS-2. Animals lacking IRS-2 progressively developed type 2 diabetes and showed insulin resistance with a defect in insulin-induced signaling in the liver, but not in skeletal muscle. At six weeks, pancreatic beta-cell mass was reduced to 83% compared to normal mice. This evidence confirms that IRS-2 has physiological functions that are not overlapping with those of IRS-1 and links its hepatic activity to the maintenance of glucose homeostasis [2].

The reference to the central nervous system is supported by a mouse model with selective reduction of IRS-2 in pancreatic beta cells and in brain regions including the hypothalamus. Irs2 expression was reduced by approximately 90% in pancreatic islets and markedly reduced in the hypothalamic arcuate nucleus, with no differences detected in the liver, muscle, or adipose tissue. The animals developed obesity, peripheral insulin resistance, and diabetes. The study does not prove that IRS-2 is the only important protein in the central nervous system, but it confirms that its alteration in this area can have systemic metabolic consequences [3].

Taken together, these studies are independent of the analyzed publication and build a coherent chain: distinct signaling profiles in cells, a major role for IRS-1 in muscle, a significant role for IRS-2 in the liver, and specific functions of IRS-2 in the brain-pancreas axis. The main common limitation is that these are primarily experiments in rodents or cells, with the possibility of biological compensations that do not fully replicate human physiology.

Conflicting evidence

The distinction between muscular IRS-1 and hepatic IRS-2 should not be interpreted as an absolute separation. In a hyperinsulinemic-euglycemic clamp experiment—a procedure that maintains stable glycemia while measuring the response to insulin—mice lacking IRS-1 and mice lacking IRS-2 both showed a reduction in insulin-stimulated whole-body glucose utilization. In mice lacking IRS-2, peripheral glucose utilization, the suppression of endogenous glucose production, and glycogen synthesis in the liver were also reduced [4].

These results do not negate the existence of differentiated roles. However, they indicate that IRS-2 also influences muscle and adipose tissue and that its function depends on the physiological context being studied. Consequently, the statement in the book is sustainable if read as a relative predominance of functions, rather than an absolute exclusivity of IRS-1 in muscle or IRS-2 in the liver and central nervous system.

Summary table of evidence

The table distinguishes the original study, which documents differentiated intracellular signals, from independent research that contextualizes their significance across different tissues.

Reference Study type Population or model Main result Direction of evidence Strength of evidence
Original study Cellular and phosphoproteomic Normal mouse brown preadipocytes, IRS-1-deficient or IRS-2-deficient IGF-1 regulated approximately 10% of 6,262 phosphorylation sites, with preferential profiles dependent on IRS-1 or IRS-2. direct confirmation moderate
[1] Animal with genetic knockout IRS-1-deficient mice; muscle and liver analysis The absence of IRS-1 reduced glucose transport and other insulin signals in muscle, with greater compensation by IRS-2 in the liver. direct confirmation moderate
[2] Animal with genetic knockout IRS-2-deficient mice The absence of IRS-2 caused hepatic insulin signaling defects, reduced beta-cell mass, and progressive diabetes. direct confirmation moderate
[3] Animal with tissue-specific alteration Mice with reduced IRS-2 in beta cells and hypothalamus Reduced IRS-2 in the brain-pancreas axis was associated with obesity, insulin resistance, and diabetes. indirect confirmation moderate
[4] Animal with genetic knockout and metabolic clamp IRS-1 or IRS-2-deficient mice The absence of IRS-2 also reduced peripheral glucose utilization, in addition to impairing hepatic functions. discordant evidence moderate

Confirmation of the evidence

Claim in the book

In section 4.2, “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, it is stated that IRS-1 and IRS-2 are not interchangeable, that they have distinct functions in tissues, and that the efficiency of the insulin signal depends on their balance, their tissue-specific expression, and their functional integrity.

Insulin/IGF-1 receptor → IRS-1 or IRS-2 → partially distinct intracellular signals → tissue-specific response → regulation of glucose metabolism

The publication subject to the Evidence Review was used in the book to support the following passage: IRS-1 and IRS-2, while sharing structural characteristics, transmit partially different intracellular signals; their functional balance can therefore contribute to an efficient and selective insulin response.

The analyzed publication directly documents a molecular segment of the chain: after stimulation with IGF-1, cells with IRS-1 or IRS-2 show preferential phosphorylation profiles and, therefore, intracellular instructions that are not entirely overlapping. Independent evidence extends this observation to the organ level in murine models. The absence of IRS-1 primarily compromises glucose transport and other insulin effects in the muscle [1]. The absence of IRS-2 significantly compromises insulin signaling in the liver and alters pancreatic beta-cell compensation [2]. The reduction of IRS-2 in the hypothalamus and beta cells also shows that this isoform participates in the central and pancreatic regulation of metabolic balance [3].

However, the narrative must be kept within precise limits. IRS-2 does not operate exclusively in the liver and central nervous system: data from metabolic clamps indicate that its absence can also reduce peripheral glucose utilization [4]. Therefore, the evidence confirms functional differences and a relative tissue-dependent predominance, not a rigid and universal division of tasks between the two isoforms.

The connection with “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi is therefore scientifically recognizable: the original study provides the mechanistic basis for the non-interchangeability of IRS-1 and IRS-2, while independent literature shows that these differences also manifest at the muscle, liver, and nervous system levels in rodents.

Overall level of confirmation

MECHANISTIC CONFIRMATION

The functional non-equivalence of IRS-1 and IRS-2 is supported by convergent results in cells and mice. Direct demonstration in humans, especially regarding tissue-specific predominance and clinical consequences, remains limited.

Conclusions

The study analyzed clearly supports, at the cellular level, that IRS-1 and IRS-2 can direct different signals following stimulation with IGF-1. This is consistent with their role as platforms that help the cell select its response to insulin.

Independent evidence in rodents confirms that IRS-1 plays a particularly important role in skeletal muscle and that IRS-2 has relevant functions in the liver, pancreatic beta cells, and the central nervous system. This distinction is not absolute, as both isoforms contribute in part to multiple tissues and metabolic processes.

The book's narrative is therefore well-supported at the mechanistic and animal level, but requires further direct validation in humans to define the extent to which the differences between IRS-1 and IRS-2 contribute to individual metabolic health and metabolic diseases.

Overall assessment

The functional difference between IRS-1 and IRS-2 is well-supported at a mechanistic level and by murine models. The idea of an IRS-1 predominance in muscle and an IRS-2 predominance in the liver and central nervous system is fairly well-supported, though not as an exclusive distinction. Clinical confirmation in humans remains limited.

References

[1] Insulin Signalling and Insulin Actions in the Muscles and Livers of Insulin-Resistant, Insulin Receptor Substrate 1-Deficient Mice

Yamauchi T, Tobe K, Tamemoto H, Ueki K, Kaburagi Y, Yamamoto-Honda R, et al., 1996

Molecular and Cellular Biology

[2] Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia.

Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, et al., 2000

Diabetes

[3] Dysregulation of insulin receptor substrate 2 in b cells and brain causes obesity and diabetes

Lin X, Taguchi A, Park S, Kushner JA, Li F, Li Y, et al., 2004

Journal of Clinical Investigation

[4] Contrasting Effects of IRS-1 Versus IRS-2 Gene Disruption on Carbohydrate and Lipid Metabolism in Vivo

Previs SF, Withers DJ, Ren JM, White MF, Shulman GI, 2000

Journal of Biological Chemistry

Editorial note

Artificial Intelligence was used solely as a tool to support editorial and documentary work. All content, interpretations, bibliographic citations and conclusions have been verified, reviewed and approved by the author, who assumes full scientific responsibility for them.

The manuscript was also subject to independent peer review prior to publication.

To ensure maximum transparency, the article's complete history — including the dates of submission, review, acceptance and publication, as well as information on the peer review process — is available on the dedicated Article History page.